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Summary
Mitochondrial genetics is complicated by heteroplasmy,
or mutant load, which may be from 1%–99%, and thus
may produce a gene dosage–type effect. Limited data are
available for genotype/phenotype correlations in disor-
ders caused by mtDNA mutations; therefore, prenatal
diagnosis for mtDNA mutations has been hindered by
an inability to predict accurately the clinical severity ex-
pected from a mutant load measured in fetal tissue. After
reviewing 44 published and 12 unpublished pedigrees,
we considered the possibility of prenatal diagnosis for
two common mtDNA mutations at nucleotide 8993.We
related the severity of symptoms to the mutant load and
predicted the clinical outcome of a given mutant load.
We also used the available data to generate empirical
recurrence risks for genetic counseling, which may be
used in conjunction with prenatal diagnosis.
Introduction
During the past decade, many pathogenic mutations
have been identified in mitochondrial (mt) DNA (Shoff-
ner and Wallace 1995). Despite the progress in mtDNA
mutation detection and diagnosis, the therapy of patients
with mitochondrial cytopathies remains largely ineffec-
tive. It is therefore necessary to offer families with an
mtDNA mutation accurate counseling about prognosis,
recurrence risk, and prevention of further cases. How-
ever, genetic counseling of families with mtDNA mu-
tations is difficult. Because mtDNA is inherited mater-
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nally, preventing the transmission of mtDNA disorders
is problematic, and little is known about recurrence
risks. Nuclear transfer between oocytes and preimplan-
tation diagnosis are possibilities, but, at present, in vitro
fertilization (IVF), by means of oocytes donated by a
woman with no mutant mtDNA, is the most feasible
method of ensuring an unaffected child. IVF, however,
is not suitable for all women, because of the financial
and emotional hardships involved and the lack of oocyte
donors.
Prenatal diagnosis for mtDNA mutations is techni-
cally possible; however, such tests have been performed
with reluctance. Predicting the severity, type, and age at
onset of symptoms caused by mtDNA mutations has
been hampered by the difficulty in interpreting the level
of heteroplasmy (the coexistence of at least two species
of mtDNA molecules within the cell). The level of het-
eroplasmy is also referred to as the “mutant load,”
which is the proportion of mutant mtDNA molecules.
There are also concerns that the mutant load may vary
among tissues and may change over time (Harding et
al. 1992; Poulton andMorten 1993). To date, there have
been few attempts to review the data on mtDNA mu-
tations in order to generate predictive data for genetic
counseling. Recently, Chinnery et al. (1997) reviewed
the published data on two common mtDNA mutations
(A3243G and A8344G) and identified a relation be-
tween mutant load in muscle (but not in blood) and the
presence of specific clinical symptoms.
In the present study, we have reviewed the data from
56 pedigrees with the two mtDNA mutations at nt
8993—8993(TrG) and 8993(TrC)—in the ATPase6
gene. These mutations are associated with symptoms
such as neurogenic muscle weakness, ataxia, and retinitis
pigmentosa (NARP; MIM 551500) (Holt et al. 1990)
and Leigh syndrome (MIM 516060) (de Vries et al.
1993). The 8993C mutation is generally considered to
be clinically milder than the 8993G mutation, and to-
gether they represent the most common mtDNA mu-
tations identified in children (Rahman et al. 1996; San-
torelli et al. 1996). The issues of tissue and age-related
variation have been addressed for the mutations at nt
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8993 and appear to be minimal (White et al., in press).
The data from the 48 8993G pedigrees and from the 8
8993C pedigrees have been used to gauge the relation-
ship between the mutant load and the severity of symp-
toms and to generate empirical recurrence risks for the
mutations at nt 8993. This information should be useful
to clinicians and genetic counselors for helping families
to make their reproductive choices and for determining
the prognosis of a child born with a mutation at nt 8993.
Material and Methods
Subject Groups
To assess genotype/phenotype correlations and to es-
timate recurrence risks, we examined reports on mem-
bers from all families in the literature with either the
8993G or the 8993C mutation (van Erven et al. 1987;
Holt et al. 1990; Sakuta et al. 1992; Shoffner et al. 1992;
Tatuch et al. 1992; Ciafaloni et al. 1993; de Vries et al.
1993; Ortiz et al. 1993; Puddu et al. 1993; Santorelli et
al. 1993, 1994, 1996, 1997; Tatuch and Robinson 1993;
Yoshinaga et al. 1993; Fryer et al. 1994; Klement et al.
1994; Lodi et al. 1994; Pastores et al. 1994; Degoul et
al. 1995; Houstek et al. 1995; Makela-Bengs et al. 1995;
Tulinius et al. 1995; Bartley et al. 1996; de Coo et al.
1996; Mak et al. 1996; Vazquez-Memije et al. 1996;
Blok et al. 1997; Degoul et al. 1997; Ferlin et al. 1997;
Seller et al. 1997; Uziel et al. 1997). Data from an ad-
ditional nine 8993G and an additional three 8993C ped-
igrees were also included (White et al., in press). Except
where specified, separate analyses were done for each
mutation group. Unexplained infant deaths were ex-
cluded from all analyses, unless developmental delay,
lactic acidosis, seizures, or dystonia were noted in the
clinical history. Miscarriages and stillbirths were ex-
cluded from all analyses.
The relationship between an individual’s clinical
symptoms (see the Clinical Scores and Outcomes sub-
section, below) and mutant load was investigated in all
individuals from the above-mentioned studies in whom
the mutant load had been measured. When more than
one tissue from an individual had been analyzed, the
mutant load used was that obtained in blood or that
obtained in muscle when blood was not available. The
relationship between the mutant load of each mother
and that of her children was investigated by means of
the mother/child pairs in which both the mother and her
offspring had a quantified mutant load. The relationship
between the mutant load of each mother and the clinical
symptoms of her children was investigated by means of
the mother/child pairs in which the mother had a quan-
tified mutant load and her offspring had clinical symp-
toms or a symptomatic status (see the Clinical Scores
and Outcomes subsection, below). Probands were ex-
cluded from all mother/child relationship analyses.
Mother/child relationships in which the mother had a
mutant load of zero were included if one or more of her
offspring (other than a proband) had a detectable mu-
tant load.
Clinical Scores and Outcomes
The severity of symptoms was measured by assigning
a score on the basis of each individual’s clinical symp-
toms or symptomatic status. A score of 1 (the least af-
fected) was assigned to asymptomatic adults; a score of
2 was assigned to asymptomatic children. These asymp-
tomatic groups were separated because an asymptomatic
child may develop symptoms at a later age. A score of
3 was assigned to individuals who were affected by mild
symptoms associated with NARP (e.g., problems with
night vision and proximal muscle weakness) or with
symptoms that may or may not be due to 8993G or
8993C (e.g., depression, migraine, and bulimia). Indi-
viduals with marked symptoms of NARP (e.g., devel-
opmental delay, mental retardation, dystonia, and
ataxia), who were alive and lacked a confirmed diagnosis
of Leigh syndrome, were assigned a score of 4. Individ-
uals with Leigh syndrome, those who had died in child-
hood as a result of Leigh-like symptoms, or those who
died in infancy (and whose deaths were not attributed
to sudden infant death syndrome) were assigned a score
of 5.
These clinical scores were dichotomized into “mild”
and “severe” outcomes for the logistic regression anal-
yses. Themild-outcome group included those individuals
with a clinical score of 1 or 2 and all individuals but
one with a score of 3. The severe-outcome group in-
cluded those individuals with a clinical score of 4 or 5
and one individual with a score of 3. That individual
was a 6-year-old child who had hypotonia in infancy,
delayed motor skills, poor vision (but no optic atrophy
or retinitis pigmentosa), delayed speech, and dysarthria
(Fryer et al. 1994). She had no ataxia or pyramidal tract
dysfunction; however, because of her age, it was thought
that any physical or mental deterioration would place
her in the symptom range of a clinical score of 4.
Statistical Analyses
Analyses were performed with SPSS for Windows
(version 7.0), Stata (version 5.0), and MLn (Rasbash et
al. 1995). The distributions of mutant load for all in-
dividuals within categories defined by symptom severity
score (1–5) have been presented as box plots. To assess
the significance of differences in the median level of mu-
tant load across categories of symptom severity, Kruskal-
Wallis one-way analyses of variance were performed.
The probabilities of a severe clinical outcome for indi-
viduals with a given mutant load were estimated by
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Figure 1 Box plots showing distributions of mutant load (%)
within categories defined by clinical score for a, the 8993G mutation,
and b, the 8993C mutation. The horizontal line across the box is the
median, and the box represents the interquartile range (25th to 75th
percentile). The bars extend to either (1) the maximum and the min-
imum values or (2) the 1.5-fold range of interquartile distance.Outliers
are represented by (x) (1.5–3 box widths away from the edge of the
box) or (*) (13 box widths away from the edge of the box).
means of a logistic regression model (see Appendix A)
fitted to the dichotomized clinical score.
To assess the relationship between the maternal mu-
tant load and the mutant load of the children, the 8993G
and 8993C subject groups were combined, since there
is no evidence to suggest that the two mutations are
transmitted from mother to child by a different mech-
anism. Mothers were divided into five categories on the
basis of their mutant load (0%–20%, 21%–40%,
41%–60%, 61%–80%, or 81%–100%), and the cate-
gories are presented as pie charts. The proportion of
children whose mothers have mutant loads that fall into
each of these five categories is represented by the slices
of the pies.
Recurrence risks, defined as the probability of a severe
outcome in a child given the mutant load in the child’s
mother, were estimated for each mutation. To allow for
variation between mothers in terms of their propensity
to pass on the mutant load (e.g., the size of their mtDNA
bottleneck), we fitted logistic regression models that in-
cluded a random-effect term for mothers (see Appendix
B). There were no children (excluding probands) with
severe outcomes whose mothers had a mutant load of
zero (a total of 18 mothers with 37 children with the
8993G mutation and 1 mother with 3 children with the
8993C mutation). The logistic regression implied a lin-
ear relationship between the mother’s and the child’s
mutant load when the mothers with a mutant load of
zero were excluded from the analyses. When the “zero
mothers” were included, the data no longer fit the sta-
tistical model implied by the data from mothers with
1%–100% mutant load. These zero mothers were there-
fore excluded from the logistic regression analyses used
to generate the log odds of adverse outcome given the
mother’s mutant load.
Results
Genotype/Phenotype Correlation
The relationship between the mutant load and the
clinical score for individuals was investigated for both
the 8993G ( ) and the 8993C ( ) muta-n  178 n  52
tions. Figure 1 shows a significant increase in median
values of percent mutant load with increasing severity
of symptoms. This is true for individuals with either the
8993G mutation or the 8993C mutation ( , forP ! .0001
both). The ranges of mutant load are wide, and inter-
quartile ranges overlap in symptom score categories 1
and 2, and 2 and 3 for the 8993G mutation, and in
symptom score categories 1 and 2 for the 8993C mu-
tation. In the higher-symptom score categories, individ-
uals with the 8993C mutation showed less variation in
mutant load than those with an 8993G mutation, which
may be partly because of the small number of subjects.
All individuals with the 8993Cmutation and a symptom
score of 3 had a mutant load of 80%, whereas some
individuals with the 8993G mutation had quite severe
symptoms with lower mutant loads. Separating patients
by sex in categories 4 and 5 showed no significant dif-
ference between the median mutant loads of males and
females (data not shown), implying that there is no ma-
jor difference in genotype/phenotype correlation be-
tween males and females.
To minimize the effect of inaccurate quantifications
and the nonuniformity of clinical investigation on the
analyses, and for ease of modeling, we dichotomized
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Figure 2 Estimated probability of severe outcome (with 95%
confidence intervals) on the basis of the mutant load of the sample
derived from the logistic regression model for a, the 8993G mutation
( ), and b, the 8993C mutation ( ).n  178 n  52
clinical scores into mild (which included asymptomatic
individuals) and severe, to generate predictive figures for
the clinical outcome. Figure 2 shows the fitted proba-
bility, with 95% confidence intervals, of a severe out-
come for the range of individual’s mutant loads, for the
8993G mutation (fig. 2a) and the 8993C mutation (fig.
2b). The probability of having severe symptoms is low
until the mutant load reaches 60%–70% for the 8993G
mutation and 80%–90% for the 8993C mutation, at
which point there is a steep increase in the probability
with increasing mutant load. The regression line for the
8993G data in figure 2a predicts a probability of .25
for a severe outcome at a mutant load of 63%, with the
probability increasing to .50, .75, and .95 at mutant
loads of 71%, 78%, and 91%, respectively. Because of
the small sample size, the relationship could not be pre-
cisely estimated for the 8993C mutation.
Relationship between Mother’s and Offspring’s Mutant
Loads
In the mother-child analyses (from which all probands
were excluded), there were 53 mothers with the 8993G
mutation and 122 children. The number of children per
mother was in the range of 1–7 (25 mothers had only
one child other than the proband). Of these 122 children,
80 had both a measured mutant load and a clinical score;
42 had only a clinical score. Eighteen mothers with 46
children had the 8993C mutation, and each mother had
between one and seven children (five mothers had only
one child other than the proband). Of these 46 children,
38 had both a measured mutant load and a clinical score;
8 had only a clinical score. We combined the 8993G
and 8993C data sets in which both mother and child
had a measured mutant load ( ) to assess then  118
proportion of children in five categories of mutant load
(0%–20%, 21%–40%, 41%–60%, 61%–80%, or
81%–100%) whose mothers were in the same categories
(fig. 3). Each pie chart represents a single category of
mothers. It is apparent that there is a greater proportion
of children with a high mutant load as the mothers’
mutant load increases, although it is possible for a
mother with a high mutant load to have a child with a
low mutant load and vice versa.
Recurrence Risks for nt 8993 Mutations
In the published nt 8993 pedigrees, many members
did not have a quantified mutant load, but essentially
all had a known clinical status. To minimize the ascer-
tainment bias inherent in our sample population, we
investigated recurrence risks using the clinical status
rather than the mutant load of the offspring. The clinical
scores were dichotomized into mild and severe out-
comes, and the data were then used to estimate recur-
rence risks via a logistic regression model (see fig. 4 and
Appendix B for equations). The model predicts an in-
creasing risk of a severe outcome with increasingmutant
load in the mother. The fitted probability of a severe
outcome in the child is plotted for a 95% range of moth-
ers’ propensity to pass on the mutation in figure 4. The
central line on this plot represents the fitted probability
for a child whose mother is “average” with respect to
passing on the mutation. The 95% range shows that at
a given mutant load, there is considerable variation in
the propensity of a woman to have a child with a severe
outcome; hence, there is a high degree of uncertainty in
the prediction. The two plots suggest a higher proba-
bility of a severe outcome at a given maternal mutant
load for the 8993G mutation than for the 8993C
mutation.
Discussion
Reliability of Mutant Load Estimates
Predicting the clinical severity or risk of recurrence
from the mutant load measured in a particular tis-
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Figure 3 Pie charts for mothers with mutant loads in categories of a, 0%–20%; b, 21%–40%; c, 41%–60%; d, 61%–80%; and e,
81%–100%. Each pie chart shows the proportion of children with these mutant loads whose mothers are in the same categories.
sue—that is, CVS or blood—depends on that mutant
load being representative of the other fetal or adult tis-
sues. A review of the published 8993G and 8993C ped-
igrees provides strong evidence to suggest that (1) there
is usually no substantial variation of the 8993G or
8993C mutant load among different fetal and adult tis-
sues and (2) the nt 8993 mutations show no substantial
age-related variation (White et al., in press). Therefore,
the mutant load of a mutation at nt 8993 measured in
a CVS or woman’s blood can be considered as repre-
sentative of the mutant load in the other fetal or adult
tissues. These observations cannot be extrapolated to all
mtDNA mutations. For example, the difference between
blood and muscle mutant loads of the MELAS 3243G
mutation increases with age (Poulton andMorten 1993),
and the 3243G blood mutant load does not correlate
with symptoms (Chinnery et al. 1997).
Some inconsistency is likely when comparing results
of 8993G or 8993C mutant loads estimated by different
techniques in different laboratories. Such differences are
unlikely to substantially affect the predicted correlation
curves relating mutant loads with outcome; however,
they will increase the uncertainty around predictions for
both the predictive clinical outcomes and recurrence
risks. The greatest variabilities in mutant load quanti-
fications are likely to be at the extreme ends of the mu-
tant load range—that is, the underestimation of a low
mutant load (!10%) and an overestimation of a high
mutant load (190%). However, the phenotypic varia-
bility at each of these mutant load ranges is quite small
(as evidenced by the narrow confidence intervals), and
modest variations are unlikely to alter the predicted
curves substantially.
When using the predictive curves with patient data, it
is essential to obtain an accurate quantification. We rec-
ommend avoiding the use of cultured cells or paraffin-
embedded tissues in predicting risk, as these samples
show more artifactual variation than blood or fresh tis-
sues (White et al., in press).
Relationship between Mutant Load and Clinical
Symptoms
Clinical scores assigned to individuals were sometimes
subjective, because of the nonuniformity of clinical in-
vestigation. Only some of the probands were investi-
gated for brain lesions, which would result in a score of
5 (for a diagnosis of Leigh syndrome), rather than 4 (for
a diagnosis of NARP). It appears that some asympto-
matic adults were not investigated fully, for example, for
ophthalmologic changes, which, if present, would have
resulted in a clinical score of 3 rather than 1. There was
also uncertainty as to the age of some of the asympto-
matic members of the families and, therefore, whether
the clinical score should have been 1 or 2.
Overlap between the asymptomatic clinical score
groups (fig. 1) was partly because of the difficulty in
accurately classifying symptom severity in these groups
but also reflects the variability in symptoms resulting
from low mutant loads. In figure 1a (8993G), most sub-
jects with symptom scores of 4 or 5 had mutant loads
of 75%. One individual, marked “*”, is an extreme
outlier, with a mutant load of 57% and a diagnosis of
Leigh syndrome (score of 5). Inspection of the figures
from the original papers (Sakuta et al. 1992; Yoshinaga
et al. 1993) suggests that the mutant load is considerably
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Figure 4 Predicted recurrence risks, with 95% range of pro-
pensity to pass on the mutation, determined by estimated variability
between mothers with identical mutant loads of between 1% and
100% of the a, 8993G mutation and the b, 8993C mutation.
157% in both blood and muscle. There are four other
outliers (marked “x” on fig. 1a) with clinical scores of
5: two probands with mutant loads of 80% and 76%
(families 6 and 10 in the study by White et al., in press),
and a proband and her sister with mutant loads of 77%
and 82%, respectively (Shoffner et al. 1992). Only one
outlier—a proband with a confirmed diagnosis of NARP
and a mutant load of 85% (family 12 in the study by
White et al., in press), who was marked “x” on figure
1b—was seen with the 8993C mutation. These outliers
may be due to factors affecting the quantifications or
may represent variations in the clinical progress of the
disorder. As with other metabolic diseases, environmen-
tal factors (particularly viral infections) and genetic
background would be expected to contribute some var-
iability to the genotype/phenotype correlation.
The presence of a “threshold” effect with mtDNA
mutations was postulated in 1983 (Howell 1983) and
has been verified by subsequent cybrid studies (Boulet
et al. 1992; Yoneda et al. 1995). This theory suggests
that there is a minimum proportion of wild-typemtDNA
molecules sufficient for ATP production, and that when
the proportion of wild-type mtDNA molecules falls be-
low this threshold, ATP production is compromised. A
threshold effect is apparent in figure 2a. The data for
the 8993C mutation are consistent with a threshold at
a higher mutant load than the 8993G mutation. There
is a higher probability of severe outcome at a given mu-
tant load for the 8993G than the 8993C mutation (fig.
2). This finding is consistent with suggestions of others
(Rahman et al. 1996; Santorelli et al. 1996) that the
8993G mutation is more severe than the 8993C
mutation.
Relationship between Mother’s and Offspring’s Mutant
Load
Rapid switching of mtDNA type, often in one gen-
eration, has been seen in Holstein cows and in humans
and has led to the formulation of the “bottleneck the-
ory.” This theory suggests that at some stage in oocyte
development, a small number of mtDNA molecules are
preferentially amplified to “repopulate” the oocyte
(Hauswirth and Laipis 1982). The bottleneck theory is
supported by the analysis of an individual’s seven oo-
cytes that showed a highly skewed distribution of the
8993G mutation (Blok et al. 1997). The theory is also
supported by the finding that ∼20% of families with the
8993G mutation appear to result from the expansion of
a de novo mutation (de Coo et al. 1996; Degoul et al.
1997; Santorelli et al. 1997; Seller et al. 1997; Uziel et
al. 1997; White et al., in press).
If only a small number of mtDNAmolecules are being
replicated to repopulate the oocyte, one would expect
that a clonal expansion of the mother’s mtDNA would
result in a woman with a high mutant load having more
oocytes with high mutant loads. Similarly, one would
expect a woman with a low mutant load to have more
oocytes with low mutant loads, since the “source” of
the clonal expansion would consist mainly of wild-type
mtDNA molecules. Can we therefore gain an indication
of the risk of having an affected child from the maternal
mutant load?
The data from the mother/child relationships are likely
to be affected by the ascertainment biases inherent in
the sample population. There is almost certainly an un-
derascertainment of clinically unaffected siblings with
the mutation (because of ethical concerns about pre-
symptomatic testing) and an overascertainment of fam-
ilies with multiple severely affected individuals in the
published literature. Although one should be mindful of
the biases, there appears to be a strong positive rela-
tionship between a mother’s blood load and the mutant
load of a mutation at nt 8993 in her offspring (fig. 3).
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The data in figure 3e are all the offspring ( ) ofn  7
one woman with a mutant load in blood of 84% and
a clinical score of 1—that is, she was asymptomatic (De-
goul et al. 1995). The figure from the original report
shows that the mtDNA fragments in the Southern blot
were very faint, and the low signal intensity may have
made the quantification unreliable. This woman gave
birth to eight children, two of whom were also asymp-
tomatic but had high mutant loads. This family shows
considerable inconsistencies with the other families in
this study, both in the correlation between the mutant
load and the severity of symptoms and in the relationship
between the maternal mutant load and the clinical symp-
toms of the offspring.
Recurrence Risks for Mutations at nt 8993
Predicted recurrence risks for both mutations at nt
8993 were generated (fig. 4) and indicate an increasing
probability of severe outcome with increasing mother’s
mutant load. However, there is a wide 95% range of
predicted probabilities, reflecting the variation inmutant
loads of children whose mothers have a mutation at nt
8993. This finding is consistent with a small bottleneck
size. It also indicates that caution is needed whenmaking
predictions about severity of symptoms in children on
the basis of a woman’s mutant load. The model gives
us an idea of the outcome for an “average” woman, but
clients must be counseled about the wide range of pos-
sible outcomes. The size of the bottleneck could be cal-
culated for each family by use of the data obtained in
this study (Poulton et al. 1998). However, the calcula-
tions would be affected by the inherent ascertainment
biases and small sample size in the families and would
be unlikely to provide more-specific recurrence risks to
a couple requiring genetic counseling than those gen-
erated in figure 4.
A number of women had no detectable mutant load
and no children, other than the proband, with symptoms
or a detectable mutant load. These cases are likely to
arise from de novo mutations that appear to be common
(see the Relationship between Mother’s and Offspring’s
Mutant Load subsection, above). However, it is possible
that some mothers of children with apparently de novo
cases had a mutant load below the limit of detection.
Since many of their children have not had mutation test-
ing (because of ethical concerns about testing presymp-
tomatic or asymptomatic children), these women cannot
be regarded as having a zero recurrence risk, and we
think it reasonable to quote a recurrence risk figure of
!10%.
The predictive data in figures 2 and 4 provide the only
figures currently available to help with genetic counsel-
ing for families with a mutation at nt 8993. Although
it must be stressed that there is uncertainty around pre-
dictions that can be made, they provide guidelines for
use by clinicians dealing with families in this situation.
The empirical recurrence risks can be used to help with
decision making during prepregnancy counseling and to
determine if prenatal diagnosis is appropriate for the
family. Furthermore, the calculated risk of a severe clin-
ical outcome made on the basis of mutant load provides
figures for use in interpreting results from a prenatal
diagnostic test, if the family chooses to take this option.
Clearly, the uncertainty about the predictions needs to
be communicated to the families, particularly for the
8993C mutation. The subject group consisting of the
8993C families was small; therefore, recurrence risks
given to families with this mutation should be accom-
panied by careful counseling about the limitations of the
data. However, as in many areas of genetic counseling,
uncertainty and making decisions on the basis of im-
precise risk estimates is a part of the process.
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Appendix A
The logistic regression model for an individual’s prob-
ability (P) of a severe clinical outcome, given the mutant
load, is , where x is the individual’sPln  b  b x0 11P
mutant load. The exponential of the parameter b1 is the
odds ratio of a severe clinical outcome for a unit increase
in an individual’s mutant load. The model was fitted
separately for data from the 8993G and 8993C muta-
tions, and the estimates are given in table A1. The es-
timates can be used to obtain an average fitted proba-
bility of severe outcome for individuals with a given
mutant load (as done for fig. 2).
Table A1
Estimate of Logistic Regression Model Parameters for the 8993G
and the 8993C Mutations
ESTIMATE (STANDARD ERROR) FOR
MUTATION
PARAMETER 8993G 8993C
Coefficient for individual’s
mutant load ( 1)b .143 (.024) .294 (.142)
Constant ( 0)b 10.092 (1.810) 25.645 (12.606)
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Appendix B
The logistic regression model for the jth child’s prob-
ability of a severe outcome, Pr(yij1), given the mother’s
mutant load, denoted xi, and including a mother-specific
random effect, ui (assumed to have a normal distribution
with mean of zero and variance of j2), is
Pr(y  1)ijln  b  b x  u .0 x i i1 Pr(y  1)ij
The exponential of the parameter is the odds ratio ofbx
a severe outcome for a unit increase in mother’s mutant
load (given the mother’s random effect ui). This model
is fitted separately to data from 8993G and 8993C mu-
tations. The estimates from table B1 can be used in the
model to obtain fitted probabilities for an individual
child, either for a range of typical mothers (as done for
fig. 4) or for an average mother (i.e., when ui 0).
Table B1
Estimates of Random-Effect Model Parameters for the 8993G and
8993C Mutation Models
ESTIMATE (STANDARD ERROR)
FOR MUTATION
PARAMETER 8993Ga 8993Cb
Coefficient for mother’s
mutant load ( )bx .046 (.018) .041 (.019)
Constant ( )b0 2.023 (0.866) 1.709 (.578)
Variation between mothers ( )2j 2.505 (1.331) 1.696 (1.628)
a We produced these estimates using the restrictive iterative gen-
eralized least squares (RIGLS) procedure and performed updates using
2d-order predictive quasilikelihood (PQL).
b Mother’s mutant load was centered at 40 to aid the estimation of
the model for the 8993C mutation (i.e., xi was replaced by [xi 40]
in the model above). The estimation of the model for the 8993C mu-
tation was RIGLS with 1st-order PQL. Estimation problems were en-
countered when we attempted 2d-order PQL, presumably because of
the small sample size.
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